Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Theranostics a ‘State-of-the-Art’ Treatment Option for Prostate Cancer
For patients with prostate cancer, theranostics may be another available treatment path to take, especially for those who need more options.
5 steps to take immediately after a prostate cancer diagnosis
Receiving a prostate cancer diagnosis can be life-altering, both mentally and physically. It's a moment filled with uncertainty, fear and countless questions
Experts suggest stripping ‘cancer’ from low-grade prostate cancer diagnoses
Cancer doctors, scientists, and patient advocates said the “cancer” label can do more harm than good, given this form of the disease doesn’t spread or kill patients.
Ultrasound technology makes prostate cancer diagnosis & treatment easier
Follow-up tests included a prostate MRI, which showed a suspicious spot for cancer on one side of the prostate. An image-guided, targeted biopsy confirmed this area to be prostate cancer of an intermediate grade. Fortunately, Bellanti was eligible for the HIFU procedure.
Medscape
58m
Adding EBRT to Brachytherapy Did Not Improve Higher-Risk Prostate Cancer Outcomes
Adding external beam radiotherapy did not improve biochemical failure outcomes or prostate cancer specific mortality in ...
FiercePharma
1h
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
WVTM 13 Birmingham on MSN
51m
Prostate cancer alert: Birmingham doctor urges earlier screenings
Prostate cancer is the most common solid organ cancer in American men and the second leading cause of cancer-related death ...
5h
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...
American Cancer Society
2d
Cancer in Men: Prostate Cancer is #1 for 118 Countries Globally
Prostate cancer is the most commonly diagnosed cancer in males in 118 of 185 countries, but it's the leading cause of death ...
5d
Early detection and knowing risk factors are key to beating prostate cancer
HOUSTON — September is Prostate Cancer Awareness Month. One in eight men will be diagnosed during their lifetime, and it's ...
Medscape
1d
IMRT vs Proton Therapy for Early Prostate Cancer?
New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...
KSTP-TV
2h
Inside Your Health: Prostate cancer screenings
More than a third of men over the age of 40 have a prostate cancer screening with a PSA test. Still, experts agree it’s unclear if the benefits of the cancer screenings using PSA tests outweigh the ...
Daily
5h
IMRT and proton therapy offer equally high QoL and tumor control for people with prostate cancer, reports study
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Radiation therapy
Erleada
Astellas Pharma
Johnson & Johnson
Enzalutamide
Feedback